Single dose of LSD formulation improves anxiety in Phase 2b trial
The Brown University Psychopharmacology Update – November 28, 2025
Source: OpenAlex
Summary
A single dose of a pharmaceutical formulation of lysergic acid diethylamide (LSD) significantly reduced anxiety in individuals with generalized anxiety disorder (GAD). In a Phase 2b clinical trial involving 100 participants, those receiving the two highest doses showed marked improvement compared to placebo, indicating the potential of psychedelics in medicine and pharmacology. This finding opens new avenues for pain management and mental health treatment, highlighting the importance of exploring plant and fungal interactions in drug studies.
Abstract
Treatment with a single dose of a pharmaceutical formulation of lysergic acid diethylamide (LSD) resulted in a dose‐dependent reduction in anxiety in individuals with generalized anxiety disorder (GAD), a Phase 2b study has found. The two highest of four tested dose strengths of the MM120 formulation demonstrated significant improvement relative to placebo.